.
MergerLinks Header Logo

Announced

Completed

A group of investors led a $103m Series B round in bit.bio.

Financials

Edit Data
Transaction Value£76m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private

biotechnology company

Acquisition

Friendly

Minority

Cross Border

Venture Capital

Private Equity

Biotechnology

Single Bidder

United Kingdom

Completed

Synopsis

Edit

A group of investors including Arch Ventures, Charles River Laboratories, Foresite Capital, National Resilience, Metaplanet, Puhua Capital and Tencent, led a $103m Series B round in bit.bio, a biotechnology company in England. "I’m thrilled that bit.bio is supported by world class investors and strategic partners. The capital will enable us to accelerate our clinical and commercial scale-up and to deliver cell therapies for every patient, everywhere," Mark Kotter, bit.bio CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US